Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | HTR5A | P47898 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 2/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.56 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8793776 | 0.91 | REV1 (0.70) | REV1SIGMAR1HTR1AADRA2AADRA2B | |
| SCHEMBL25825939 | 0.91 | REV1 (0.55) | REV1SIGMAR1HTR1AADRA2AADRA2B | |
| SCHEMBL10383284 | 0.85 | ABCB1 (0.74) | REV1SIGMAR1HTR1AADRA2AADRA2B | |
| SCHEMBL10383113 | 0.83 | EBP (0.58) | SIGMAR1TMEM97ABCB1ABCG2CHRNA7 | |
| SCHEMBL30073105 | 0.83 | SIGMAR1 (0.60) | SIGMAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL3050371 | 0.82 | REV1 (0.84) | REV1KMT2AABCB1ABCC1ABCG2 | |
| SCHEMBL3693352 | 0.82 | SIGMAR1 (0.75) | REV1SIGMAR1HTR1AADRA2AADRA2B | |
| SCHEMBL10383389 | 0.81 | SIGMAR1 (0.63) | SIGMAR1TMEM97ABCB1KDM4EMAPT | |
| SCHEMBL5449836 | 0.81 | HTR1A (0.54) | REV1SIGMAR1HTR1AADRA2AADRA2B | |
| SCHEMBL18356020 | 0.81 | SIGMAR1 (0.51) | REV1SIGMAR1HTR1AADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| EP-2155192-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | Sterix Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008117061-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| US-5318963-A | Heterocyclic hydrazide derivatives of monocyclic β-lactam antibiotics | E. R. SQUIBB & SONS, INC. (US) | 1994-06-07 | — | — | US | disclosed |
| EP-0227986-B1 | ISOINDOLINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-03-24 | — | — | EP | disclosed |
| US-4987235-A | Isoindoline derivatives and processes for their preparation | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| US-4958029-A | Process for the production of isoindoline derivatives, novel intermediates and process for their production | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-09-18 | — | — | US | disclosed |
| EP-0275064-A2 | Process for the production of isoindoline derivatives, novel intermediates and process for their production | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-07-20 | — | — | EP | disclosed |
| EP-0227986-A1 | Isoindoline derivatives and processes for their preparation | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222299-A1 | COMPOUND | MKI67, VHL, MYC | REV1 1520/4885SIGMAR1 4163/4885HTR1A 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.